Atostar Plus Tab.
Negotiable Min Order Quantity Unit
- Required Quantity
-
- Place of Origin
- Payment Terms
- Negotiable
- Production method
- Negotiable
- Shipping / Lead Time
- Negotiable / Negotiable
- Keyword
- atorvastatin, amloidipine, circulatory system
- Category
- Health & Medical
DONGWHA PHARM CO LTD
- Country / Year Established
- South Korea / 1897
- Business type
- Manufacturer
- Verified Certificate
-
16
Product name | Atostar Plus Tab. | Certification | - |
---|---|---|---|
Category | Health & Medical | Ingredients | - |
Keyword | atorvastatin , amloidipine , circulatory system | Unit Size | - |
Brand name | - | Unit Weigh | - |
origin | Stock | - | |
Supply type | - | HS code | - |
Product Information
1. Category
: Ethical > Circulatory System
2. Ingredients
: 1 tab. contains
amlodipine besylate......6.94mg(5mg as amlodipine)
atorvastatin calcium anhydrous......10.35mg(10mg as atorvastatin)
3. Indications
: ATOSTARPLUS is indicated in patients for whom treatment with both amlodipine and atorvastatin is appropriate.
▶amloidipine
hypertension, coronary artery disease(CAD)
▶atorvastatin
prevention of cardiovascular disease, heterozygous familial and nonfamilial hypercholesterolemia, elevated serum TG levels, primary dysbetalipoproteinemia, homozygous familial hypercholesterolemia
4. Dosage
: Dosage of ATOSTARPLUS must be individualized on the basis of both effectiveness and
tolerance for each individual component in the treatment of hypertension/angina and hyperlipidemia.
▶amlidipine
The usual initial antihypertensive oral dose of amlodipine is 5 mg once daily with a maximum dose of 10 mg once daily.
▶atorvastatin
The patient should be placed on a standard cholesterol-lowering diet before receiving
atorvastatin and should continue on this diet during treatment with atorvastatin.
5. Pack Size
: 30T, 100T
6. Related Disease
: Cardiovascular system
B2B Trade
Price (FOB) | Negotiable | transportation | - |
---|---|---|---|
MOQ | Negotiable | Leadtime | Negotiable |
Payment Options | Negotiable | Shipping time | Negotiable |
- President
- KI HWAN PARK
- Address
- 6-8F, 24, NAMDAEMUN-RO, 9-GIL, JUNG-GU, SEOUL, 04522, KOREA, Jung-gu, Seoul, Korea
- Product Category
- Pharmaceuticals
- Year Established
- 1897
- No. of Total Employees
- 501-1000
- Company introduction
-
In 1897, a small company named ‘Dong WhaYakbang’ was established in Jeong-dong, where Western culture was introduced ata turbulent time in Korean history. A royal court officer of the ChosunDynasty, Byung Ho Min, created Korea’s first Western-style medicine byintegrating the advantages of Western medical techniques into the royal court’ssecret recipe.
This digestive medicine, known as WhalMyung Su, meaning ‘life-saving water’, soothed people’s pain in those turbulenttimes and became a reliable “comrade” for independence fighters. Since itscreation, Whal Myung Su has been loved as the nation’s favorite digestivemedicine for 117 years amid ever-changing social circumstances and greatturmoil due to the company’s conviction that ‘We will save people with goodmedicine’.
We run our company according to the beliefthat making medicine is not a simple business activity, but a sacred andbeautiful duty that brings happiness to humans.
Honorable titles bestowed by the people,such as ‘The First’ or ‘The Best’, are earned through such a conviction.
Now, Dong Wha Pharm, as Korea’s first andoldest pharmaceutical company, is ready to launch a new era of 100 years basedon such pride. We will abide by our founder’s first intent, ‘Do not make anymedicines but good medicines’. We will be reborn as a self-regulating, adaptivecompany through change and innovation. Based on our accumulated technology and experience,we will make new products of the highest quality. With our happiness managementphilosophy, we will make Dong Wha as the company where each employee can havebig dreams.
Lastly, we will contribute to human healthand happiness. Please join us in exploring this new era.
* Dong Wha Pharm Research Institute, the Backbone of New MedicineDevelopment
Since its establishment in 1973, Dong WhaPharm Research Institute has developed numerous superior medicines and the mostadvanced drugs. It is now set to become a global hub for new drug development.
In order to create a new world-class drug,the research center will focus on R&D (Research and Development), andexpand its assistance and investment on fostering professional human resources.
* World-class advanced production facilities, Chungju cGMP plant
In 2009, at the Chungju Industrial Complex,Dong Wha Pharm completed the construction of state-of-the-art production facilities,comprising of four stories aboveground and one underground level with a totalof 82,500m2 including total floor space of 52,644m2.
The Chungju Plant is equipped withequipment and facilities that satisfy Current Good Manufacturing Practice(cGMP) Regulations of US F. D. A. In addition, the plant has been evaluated asa world-class pharmaceutical company by the installment of high-tech plantautomation system.
Dong Wha Pharm pursues 100% zero defectswith its independent quality assurance system, which encompasses the procurementof raw materials, production processes, packaging and shipment.
- Main Markets
-
Germany
Indonesia
Japan
Mexico
Portugal
Spain
U.S.A
Viet Nam
- Factory Information
-
DONG WHA CHUNGJU PLANT
- Main Product
Related Products
Covid 19 Detection
PRF BOX Implant
Jeju Sasa Extract
DISSECTING MEDICAL STUDENT KIT ANATOMY BIOLOGY STAINLESS
Bone Expander Kit Price